Brokerages expect that Check Cap Ltd (NASDAQ:CHEK) will report earnings of ($0.46) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Check Cap’s earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.50). Check Cap posted earnings per share of ($0.69) in the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The company is scheduled to report its next earnings results on Tuesday, July 30th.
According to Zacks, analysts expect that Check Cap will report full year earnings of ($1.69) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.46). For the next year, analysts expect that the firm will report earnings of ($1.22) per share, with EPS estimates ranging from ($1.85) to ($0.59). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Check Cap.
Check Cap (NASDAQ:CHEK) last announced its earnings results on Monday, May 13th. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03.
Several research analysts recently issued reports on the company. Zacks Investment Research raised HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Beyondspring in a research report on Wednesday, July 10th.
Shares of NASDAQ:CHEK traded up $0.03 during mid-day trading on Friday, hitting $2.07. 8,403 shares of the company traded hands. The stock has a market cap of $3.26 million and a PE ratio of -0.75. Check Cap has a 12-month low of $1.62 and a 12-month high of $4.50. The firm’s 50-day moving average price is $2.21.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Recommended Story: Beige Book
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.